These effects often relate to slowed gastric emptying and can be managed with smaller bites, slower eating, reduced fat intake during titration, and adequate hydration
2015;107(12):djv275
Studies on insulinotrophic and anorexigenic effects of GLP-1 only recently have led to the development of a new class of drugs, often referred to as incretin drugs, which act as GLP-1 receptor agonists (GLP-1RAs) and are currently implemented in therapy for T2DM [13]
Schedule prompt medical evaluation (within 24-48 hours) for: Gradually worsening shortness of breath over days to weeks Dyspnea with exertion that is new or significantly worse than baseline Breathing difficulty accompanied by persistent cough or fever Leg swelling, weight gain, or orthopnea (difficulty breathing when lying flat) Respiratory symptoms associated with severe ongoing nausea, vomiting, or inability to maintain hydration Patients should not discontinue GLP-1 medications without medical guidance (except in cases of suspected severe allergic reactions), but should contact their healthcare provider promptly to discuss respiratory symptoms
Neither compound is listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems
Unfortunately, many people unknowingly fall into preventable weight loss mistakes on GLP-1s treatment that slow results, trigger side effects, or risk safety